Witnessing the stock’s movement on the chart, on Wednesday, Blueprint Medicines Corp (NASDAQ: BPMC) had a quiet start as it plunged -0.01% to $128.25, before settling in for the price of $128.26 at the close. Taking a more long-term approach, BPMC posted a 52-week range of $73.04-$128.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 31.87%. Meanwhile, its Annual Earning per share during the time was 31.87%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 34.23%. This publicly-traded company’s shares outstanding now amounts to $64.56 million, simultaneously with a float of $62.30 million. The organization now has a market capitalization sitting at $8.29 billion. At the time of writing, stock’s 50-day Moving Average stood at $106.16, while the 200-day Moving Average is $96.38.
Blueprint Medicines Corp (BPMC) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Blueprint Medicines Corp’s current insider ownership accounts for 3.67%, in contrast to 106.82% institutional ownership. According to the most recent insider trade that took place on Jun 03 ’25, this organization’s CHIEF SCIENTIFIC OFFICER sold 2,659 shares at the rate of 127.88, making the entire transaction reach 340,033 in total value, affecting insider ownership by 54,206. Preceding that transaction, on May 27 ’25, Company’s Director sold 5,000 for 101.14, making the whole transaction’s value amount to 505,692. This particular insider is now the holder of 146,630 in total.
Blueprint Medicines Corp (BPMC) Earnings and Revenue Records
Blueprint Medicines Corp’s EPS increase for this current 12-month fiscal period is 34.23% and is forecasted to reach 0.92 in the upcoming year.
Blueprint Medicines Corp (NASDAQ: BPMC) Trading Performance Indicators
Let’s observe the current performance indicators for Blueprint Medicines Corp (BPMC). It’s Quick Ratio in the last reported quarter now stands at 2.75. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.75.
In the same vein, BPMC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.46, a figure that is expected to reach -0.44 in the next quarter, and analysts are predicting that it will be 0.92 at the market close of one year from today.
Technical Analysis of Blueprint Medicines Corp (BPMC)
Going through the that latest performance of [Blueprint Medicines Corp, BPMC]. Its last 5-days volume of 3.46 million indicated improvement to the volume of 1.97 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 76.10% While, its Average True Range was 1.27.
Raw Stochastic average of Blueprint Medicines Corp (BPMC) in the period of the previous 100 days is set at 99.64%, which indicates a major rise in contrast to 75.16% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.95% that was lower than 56.73% volatility it exhibited in the past 100-days period.
